Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX is a promising epigenetics company that uses its Nucleosomics platform to develop easy-to-use, cost-effective blood tests for diagnosing and monitoring diseases such as cancer and conditions associated with NETosis. The company's current positive cash position indicates enough capital to sustain operations until the mid-2026, but potential for future growth and revenue generation will depend on successful validation and adoption of their tests in clinical settings. The company's partnerships, regulatory progress, and evidence-based publications will be important catalysts to watch for in the near future to assess their potential impact on market adoption and financial success.

Bears say

VolitionRX is facing multiple risk factors related to its clinical and regulatory compliance, potential partnerships, commercialization, legal and intellectual property issues, and market share. The recent reverse stock split, ongoing platform validation, and lack of tangible commercial traction are key near-term catalysts that may impact investor sentiment. The company's financial results for 2025 showed lower than expected revenue and higher net loss, while discussions with potential licensing partners may drive future revenue growth. However, the company will likely need time to rebuild credibility with the market and address concerns about potential dilution or balance sheet actions.

Volitionrx Limited (VNRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.